VYNE Therapeutics (NASDAQ:VYNE) Announces Quarterly Earnings Results

VYNE Therapeutics (NASDAQ:VYNE) posted its quarterly earnings data on Thursday. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.02, Zacks reports. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.13 million. VYNE Therapeutics had a negative net margin of 8,097.69% and a negative return on equity of 77.57%.

VYNE Therapeutics Stock Down 0.3%

Shares of VYNE Therapeutics stock traded down $0.00 during trading on Friday, hitting $0.35. 3,199,539 shares of the stock traded hands, compared to its average volume of 1,245,156. The stock has a market cap of $8.97 million, a price-to-earnings ratio of -0.39 and a beta of 1.95. VYNE Therapeutics has a 52 week low of $0.28 and a 52 week high of $4.30. The firm’s fifty day moving average is $0.34 and its 200-day moving average is $0.80.

Hedge Funds Weigh In On VYNE Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. lifted its stake in shares of VYNE Therapeutics by 87.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock valued at $1,063,000 after acquiring an additional 300,000 shares during the last quarter. Jane Street Group LLC purchased a new position in VYNE Therapeutics in the 2nd quarter worth approximately $206,000. Finally, Boothbay Fund Management LLC bought a new stake in VYNE Therapeutics in the second quarter valued at approximately $176,000. Institutional investors own 83.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Lifesci Capital lowered VYNE Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 30th. HC Wainwright cut shares of VYNE Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 30th. BTIG Research downgraded shares of VYNE Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, July 31st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of VYNE Therapeutics in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $6.25.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.